PharmaMar . ( villancico ) .

Con mi cohete sabanero
voy camino de Colmenar
Con mi cohete sabanero
voy camino de Colmenar

Si me ven, si me ven
voy camino de Colmenar
Si me ven, si me ven
voy camino de Colmenar ... 

ZEPSYRE® ( SMALL CELL LUNG CANCER ) Según Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center .

""  Lurbinectedin has shown evidence of activity in recurrent Small Cell Lung Cancer, both as a single agent and when given in combination with doxorubicin, a chemotherapy drug "".

Small Cell Lung Cancer: Future Directions in Care .

Insights From: Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center.

Published: Thursday, Jan 02, 2020 .

“It is great to finally see some new therapeutic options arriving for small cell lung cancer patients, who represent a major unmet medical need,” said Charles Rudin, MD, PhD, chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and principal investigator of the NCI Small Cell Lung Cancer Consortium.

“I have been following the emerging clinical trial data on lurbinectedin, which suggest appealing efficacy and a tolerable safety profile. I believe many treating physicians may welcome lurbinectedin, if approved, as a new standard of care option for their patients with recurrent small cell lung cancer” . ...

YONDELIS® // LEUCEMIA . Trabectedin Targets Leukemic Cells and Restores Immune Cell Function in Models of Chronic Lymphocytic Leukemia .

Cancer Therapy Advisor // January 2, 2020 // Luisa Torres, Ph .

The marine-derived compound trabectedin depletes both human primary leukemic cells and myeloid-derived suppressor cells, according to a new study published in Cancer Immunology Research.1 The researchers think their findings could lead to a new therapy that targets both leukemic cells and the protumor microenvironment, repairing the immune dysfunction that is characteristic of chronic lymphocytic leukemia (CLL).

CLL is characterized by lymphocyte accumulation in the blood, bone marrow, and lymphoid tissues.2 Recent advances in CLL therapy have come from finding and targeting the appropriate molecular pathways of the disease, explained Kanti R. Rai, MD, a professor of medicine and molecular medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell who wasn’t involved in the study. Dr Rai said that, for instance, the Bruton tyrosine kinase inhibitor ibrutinib binds to the receptor and affects B-cell–receptor signaling. Another drug, venetoclax, an antagonist to BCL2, can effectively induce apoptosis in CLL cells. However, treatment of this disease remains challenging due to its immunosuppressive nature. “If we [are] to attain a cure, newer compounds have to be identified which have a different mechanism of controlling CLL,” he said.

...

La Inversión en Oncología Dispara las Adquisiciones en la Industria Farmacéutica .

Ana Medina // 03/01/2020 .

La industria farmacéutica realizó operaciones por más de 532.000 millones de dólares en 2019, un 13% más, encabezadas por la compra de Celgene por BMS por 74.000 millones. Reforzarse en fármacos contra el cáncer es uno de los objetivos de las empresas

La industria farmacéutica sigue marcando récord de fusiones y adquisiciones desde 2002, incluso en 2015 tras descontar la renuncia de Pfizer a hacerse con Allergan por 160.000 millones de dólares. Las empresas farmacéuticas y de salud hicieron compras por valor de 532.280 millones de dólares (474.550 millones de euros) en el mundo el año pasado, un 12,8% más, según datos de Dealogic, frente al retroceso del valor de las adquisiciones globales, que ascendió a 3,79 billones de dólares, un 2% menos. ...

La vacuna contra la gripe podría usarse como tratamiento para “calentar” tumores humanos .